Skip to main content

Table 3 Grade 3–4 immune related adverse events divided by study arm (N = 30 patients)

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

  Any Grade Grade 3 Grade 4 Grade 3/4 Ipi 3 mg/kg Grade 3/4 Ipi 10 mg/kg
No. Pts. % No. Pts. % No. Pts. % No. Pts. % No. Pts. %
Adrenal insufficiency 10 33 2 7 0 0 0 0 2 7
Hypophysitis 2 7 2 7 0 0 0 0 2 7
Diarrhea/Colitis 15 50 3 10 0 0 2 7 1 3
AST/ALT 28 93 5 17 1 3 2 7 4 13
Lipase increased 9 30 3 10 0 0 0 0 3 10
Rash, maculo-papular 14 47 7 23 0 0 4 13 3 10
Pneumonitis 1 3 1 3 0 0 0 0 1 3
Autoimmune nephritis 1 3 1 3 0 0 0 0 1 3